DRUG
NNC0487-0111 A
Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
Status
Completed
Phase
Phase 1
Enrollment
36
Locations
1
Results
Not posted
Publications
0
Study summary
The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2. The aim of the study is to see how safe the study medicine is and how it behaves in human body. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) and which treatment they get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors but has previously been tested in humans. This study will last for up to 53 days.
Interventions
DRUG
Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
DRUG
Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.
Timeline
First posted
Aug 13, 2025
Study start
Aug 11, 2025
Primary completion
Dec 20, 2025
Study completion
Dec 20, 2025
Results posted
Not reported
Registry updated
Feb 17, 2026
Outcomes
Number of treatment emergent adverse events (TEAEs)
Time frame · From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23)
Number of events
AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)
h\*nmol/L
Cmax,SD; the maximum plasma concentration of NNC0487-0111 after a single dose
Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)
nmol/L
tmax,SD; the time of maximum plasma concentration of NNC0487-0111 after a single dose
Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)
h
t1/2,SD; the terminal half-life of NNC0487-0111 after a single dose
Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)
h
Relative change in body weight
Time frame · From baseline Day 1 until completion of the end of study visit (Day 23)
Change in fasting plasma glucose
Time frame · From baseline Day 1 until completion of the end of study visit (Day 23)
mmol/L
Eligibility
Inclusion Criteria: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index between 24.0 and 34.9 kg/m2 (both inclusive) at screening. Overweight and obesity should be due to excess adipose tissue, as judged by the investigator, with a body weight (more than or equal to) ≥ 65.0 kg at screening. 4. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: 1. Any condition, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. 2. HbA1c ≥ 6.5 percent (%) \[48 milimol per mole (mmol/mol)\] at screening. 3. Any laboratory safety parameters at screening outside the below laboratory ranges: * Vitamin D (25-hydroxycholecalciferol) less than (\<) 12 nanogram per mililiter (ng/mL) \[30 nanometer (nM)\] at screening * Parathyroid hormone (PTH) outside normal range at screening * Total calcium outside normal range at screening * Amylase ≥ 2 times upper limit of normal at screening * Lipase ≥ 2 times upper limit of normal at screening * Calcitonin ≥ 50 picogram per mililiter (pg/mL) at screening
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Jinan Central Hospital
Jinan, Shandong, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Novo Nordisk · Obesity · Heart Failure
Phase 3
Recruiting
5,610
2026-07
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
Novo Nordisk · Obesity
Phase 3
Recruiting
1,150
2026-07
Novo Nordisk · Obesity · Knee Osteoarthritis (OA)
Phase 3
Recruiting
400
2026-07
Novo Nordisk · Obesity
Phase 3
Recruiting
600
2026-07
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
400
2026-07
Novo Nordisk · Diabetes Mellitus · Overweight
Phase 3
Recruiting
630
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.